
SESN
Healthcare · Biotechnology · $128.0M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2023
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 28, 2023 | Before the open | -2.20 | -0.80 | +63.6% |
| Nov 7, 2022 | Before the open | -3.10 | 2.00 | +164.5% |
| Aug 8, 2022 | Before the open | -2.60 | -3.20 | -23.1% |
| May 9, 2022 | Before the open | -2.00 | -0.00 | +99.8% |
| Feb 28, 2022 | Before the open | -1.47 | 0.80 | +154.4% |
| Nov 8, 2021 | Before the open | -1.40 | 7.20 | +614.3% |
| Aug 9, 2021 | Before the open | -1.27 | -3.00 | -136.2% |
| May 10, 2021 | Before the open | -1.53 | -7.00 | -357.5% |
| Mar 15, 2021 | Before the open | -0.11 | -0.11 | 0.0% |
| Nov 9, 2020 | Before the open | -0.08 | -0.19 | -137.5% |
| Aug 10, 2020 | Before the open | -0.09 | -0.24 | -166.7% |
| May 11, 2020 | Before the open | -0.09 | 0.31 | +444.4% |
| Mar 16, 2020 | Before the open | -0.08 |
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive…
| -0.32 |
| -300.0% |
| Nov 12, 2019 | Before the open | -0.11 | -0.13 | -18.2% |
| Aug 8, 2019 | After the close | -0.11 | -0.67 | -509.1% |
| May 10, 2019 | After the close | -0.09 | -0.08 | +11.1% |
| Mar 1, 2019 | After the close | -0.08 | -0.09 | -12.5% |
| Nov 8, 2018 | Before the open | -0.10 | -0.18 | -80.0% |
| Aug 14, 2018 | Before the open | -0.14 | -0.16 | -14.3% |
| Apr 2, 2018 | After the close | -0.17 | -0.22 | -29.4% |